November 23, 2013
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
EMA committee recommends approval of Xigduo
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
AstraZeneca and Bristol-Meyers Squibb announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use supports the approval of combination dapagliflozin and metformin for treatment of adults with type 2 diabetes, according to a press release.
The treatment (Xigduo, AstraZeneca and Bristol-Myers Squibb) is a tablet designed to be taken twice daily to improve glycemic control in patients whose current metformin-based treatment regimen is inadequate or in those taking a combination of dapagliflozin and metformin as separate tablets.
The committee’s positive opinion will be reviewed by the European Commission, which has the authority to approve medicines for the European Union.